Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that preclinical data from two novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE